Experimental findings demonstrate that charge-anchored pleuromutilin breaches anionic barriers in antibiotic-resistant bacteria, suggesting a new approach for overcoming resistance.
Antimicrobial resistance threatens health, and new agents are needed. Lefamulin is the only approved antibiotic of a new class in two decades. It targets the 50S peptidyl transferase center (PTC). Its efficacy against multidrug-resistant pathogens is limited by anionic envelopes, limiting penetration. We report a charge-anchored pleuromutilin exploiting an electrostatic Trojan horse to breach barriers and engage the ribosome. An N-pyridinium provides a cationic localizer. A two-step mechanism operates. Long-range electrostatics enrich ligands at anionic interfaces and the PTC. Short-range interactions secure high-affinity placement of the tricyclic core. Computer simulations support the occupancy of the activity pocket and the field-guided orientation of the cationic side chain for PNY-6b. Proteomics highlights ribosomal proteins as dominant targets. Cellular assays show biofilm eradication and membrane depolarization. In murine infections, PNY-6b lowers burden and improves survival. Electrostatic complementarity offers a generalizable design principle for targets with electrostatic fields and for pathogens with poor envelope permeability.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: